Research ArticleClinical Studies

Comparison of Quality of Life and Injection Site Reactions After Switching from Degarelix 80 mg to 480 mg in Advanced Prostate Cancer: A Prospective Trial

KEIICHIRO MIYAJIMA, TAKAFUMI YANAGISAWA, HIROTAKA SUZUKI, WATARU FUKUOKAYA, KEIGO SAKANAKA, KOKI OBAYASHI, JUN MIKI and TAKAHIRO KIMURA
Anticancer Research April 2023, 43 (4) 1611-1621; DOI: https://doi.org/10.21873/anticanres.16311

Article Information

vol. 43 no. 4 1611-1621
DOI 
https://doi.org/10.21873/anticanres.16311
PubMed 
36974827
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received January 4, 2023
  • Revision received January 16, 2023
  • Accepted January 17, 2023
  • Published online March 27, 2023.
Copyright & Usage 
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. KEIICHIRO MIYAJIMA,
  2. TAKAFUMI YANAGISAWA⇑,
  3. HIROTAKA SUZUKI,
  4. WATARU FUKUOKAYA,
  5. KEIGO SAKANAKA,
  6. KOKI OBAYASHI,
  7. JUN MIKI and
  8. TAKAHIRO KIMURA
  1. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
  1. Correspondence to: Takafumi Yanagisawa, MD, Ph.D., Department of Urology, The Jikei University School of Medicine, 3-25-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471 Japan. Tel: +81 334331111, Fax: +81 334331111, e-mail: t.yanagisawa.jikei{at}gmail.com
View Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Comparison of Quality of Life and Injection Site Reactions After Switching from Degarelix 80 mg to 480 mg in Advanced Prostate Cancer: A Prospective Trial
KEIICHIRO MIYAJIMA, TAKAFUMI YANAGISAWA, HIROTAKA SUZUKI, WATARU FUKUOKAYA, KEIGO SAKANAKA, KOKI OBAYASHI, JUN MIKI, TAKAHIRO KIMURA
Anticancer Research Apr 2023, 43 (4) 1611-1621; DOI: 10.21873/anticanres.16311
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords